Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag), Opsynvi® (macitentan and tadalafil), and Veletri® (thermostable epoprostenol).

“We are thrilled to have Rainer join us at such a critical juncture for the seralutinib program. The global Phase 3 PROSERA Study is well underway with multiple active clinical sites, putting us on track to reach our goal of having more than 20 sites activated by year end to support our enrollment timeline,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. “Rainer’s extensive experience in successfully developing and launching multiple PAH therapies as a global medical affairs leader will perfectly complement the strong development and commercial teams we have brought together at Gossamer.”

“Seralutinib represents an important new mechanism of action as an inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor targeting the underlying proliferative, inflammatory, and fibrotic pathways operative in PAH,” said Dr. Zimmermann. “I am excited to join the Gossamer team and look forward to contributing to our efforts to bring this promising therapy to patients with PAH.”

Prior to his role at Johnson & Johnson, Dr. Zimmermann served in similar roles at Actelion, where he started his career in the biopharmaceutical industry as the global safety physician for the macitentan and selexipag programs. Dr. Zimmermann received his medical degree from the University of Aachen, receiving additional training at several university hospitals, including University of Oxford and the Children’s Hospital at the University of Würzburg. For nine years, Dr. Zimmerman oversaw the clinic for children with PAH/PH at the Heart Center, University of Giessen, Germany. In his role at Johnson & Johnson, Dr. Zimmermann organized the PH Forum, a company sponsored educational event, which has become the largest annual, global PH scientific conference.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.

Forward Looking Statements

Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential benefits of seralutinib and the anticipated timing of activating sites in the Phase 3 clinical program for seralutinib. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials for seralutinib; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for seralutinib; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of seralutinib that may limit its development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for seralutinib; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com